Release Date: October 7, 2021
Valid for Credit Through: October 7, 2022
This activity is jointly provided by
The Consortium of Multiple Sclerosis Centers (CMSC) and
Catamount Medical Education.
Supported by an independent educational grant from Biogen.
Credit Available
- Physicians— maximum of 0.5 AMA PRA Category 1 Credit(s)™
- Nurses— maximum of 0.5 contact hours of nursing continuing professional development (NCPD) (0.5 in the area of pharmacology)
- Pharmacists— maximum of 0.5 contact hours of continuing pharmacy education credit
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of neurology physicians, nurse practitioners, PAs, pharmacists, and other healthcare professionals involved in the care of patients living with MS.
Program Overview
This 30-minute (1,800 seconds) activity will provide an overview of evidence related to vaccinations in people with MS on disease-modifying therapy, including some of the latest data and guidance related to COVID-19 vaccines.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Analyze mechanisms of immune response to vaccinations in relation to MS disease-modifying therapies
Review recommendations for vaccination, including the use of COVID-19 vaccines, for people living with MS
Faculty
Anne H. Cross, MD, FAAN
Professor of Neurology
Manny and Rosalyn Rosenthal and Dr. John L. Trotter MS Center Chair in Neuroimmunology
Section Head of the Neuroimmunology/MS Section
Washington University School of Medicine